Phase II randomized placebo-controlled trial of prostvac (PSA-tricom) in patients with clinically localized cancer undergoing active surveillance
Ended Awarded Last action
- Contract number
- HHSN26100006
- Awardee
-
University Of Arizona UEI ED44Y3W6P7B9 Part of State Of Arizona
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,513,111
Award facts
- Opportunity
-
- N01CN0501469 Solicitation number
- Contract value 90% obligated
-
- $2,513,110.92 Current, with exercised options
- $2,789,411.92 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Tucson, AZ 85719, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$5 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $0 | |
| Funding Only Action | -$186,734 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Exercise an Option | $168,543 | |
| Exercise an Option | $116,867 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $972,365 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Original award | $1,442,075 |
Show all 15
About this award
The University of Arizona, doing business as the Arizona Board of Regents, has been awarded a $2,789,411.92 cost-type delivery order contract by the National Cancer Institute (NCI) to conduct a Phase II randomized, placebo-controlled clinical trial of the prostate cancer vaccine Prostvac (PSA-TRICOM) in patients with clinically localized prostate cancer undergoing active surveillance. This contract supports the NCI's Cancer Prevention Agent Development Program 2012-2017 and does not have a set-aside designation. The University of Arizona, as a public research university and Hispanic Serving Institution, has extensive capabilities in biomedical sciences and clinical research to support this study examining a novel cancer prevention approach. The contract has a period of performance through September 15, 2023.
Quick answers
Who was awarded contract HHSN26100006?
HHSN26100006 was awarded to University Of Arizona by National Cancer Institute (National Institutes of Health) on September 12, 2014.
How much is contract HHSN26100006 worth?
The government has obligated $2,513,111 on HHSN26100006. Its potential value, with all options, is $2,789,412.
Is contract HHSN26100006 an order under another contract?
Yes. HHSN26100006 is a delivery order under HHSN261201200031I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.
Was contract HHSN26100006 competed?
The extent of competition for HHSN26100006 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award